{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-22-020809","form_type":"8-K","ticker":"IMDX","cik":"0001642380","company_name":"Insight Molecular Diagnostics Inc.","filed_at":"2022-08-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:56.501864+00:00","generated_at":"2026-06-24T06:31:24.760715+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Oncocyte appoints independent director John Peter Gutfreund; he and fund invest $10.5M","bullets":["John Peter Gutfreund elected independent director effective July 28, 2022; to chair Finance Committee.","Gutfreund invested $1M in Series A Preferred Stock (1,176.48 shares) in April 2022 registered direct offering.","Halle Special Situations Fund LLC, affiliated with Gutfreund, purchased ~$9.5M in common stock and warrants in April 2022.","CEO expects to bring three major products through reimbursement and to market over next four quarters."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-22-020809","json":"https://secwatch.observer/filing/0001493152-22-020809.json","markdown":"https://secwatch.observer/filing/0001493152-22-020809.md","text":"https://secwatch.observer/filing/0001493152-22-020809.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1642380/000149315222020809/0001493152-22-020809-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1642380/000149315222020809/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T06:31:24.760715+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4feb797aec","claim":"John Peter Gutfreund was elected as Director at Insight Molecular Diagnostics Inc..","evidence_excerpt":"Effective July 28, 2022, the Board of Directors (the “Board”) of Oncocyte Corporation (“Oncocyte” or the “Company”) elected John Peter Gutfreund, age 36, to serve as a director on the Board, with a term that expires at the Annual Meeting of Shareholders of the Company to be held in 2023 or until his earlier resignation or removal.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1642380/000149315222020809/0001493152-22-020809-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"elected"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}